Divi's Laboratories Limited (BOM:532488)

Verve Therapeutics Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	96,520	93,600	78,450	77,670	89,598	69,694
Other Revenue	-	-	-	-	0.9	0.7
Revenue	96,520	93,600	78,450	77,670	89,599	69,695
Revenue Growth (YoY)	17.92%	19.31%	1.00%	-13.31%	28.56%	29.20%
Cost of Revenue	38,280	37,250	33,520	32,740	31,662	24,771
Gross Profit	58,240	56,350	44,930	44,930	57,938	44,924
Selling, General & Admin	13,060	12,580	11,060	9,870	9,571	8,367
Other Operating Expenses	14,400	14,050	11,780	11,370	9,526	7,853
Operating Expenses	31,630	30,650	26,620	24,670	22,212	18,776
Operating Income	26,610	25,700	18,310	20,260	35,726	26,148
Interest Expense	-50	-20	-30	-	-3.7	-3.9
Interest & Investment Income	2,950	2,950	3,010	2,050	689.6	572.4
Currency Exchange Gain (Loss)	880	480	300	1,300	405.8	-43.8
Other Non Operating Income (Expenses)	50	40	30	40	38.1	21.2
EBT Excluding Unusual Items	30,440	29,150	21,620	23,650	36,856	26,694
Gain (Loss) on Sale of Investments	50	50	50	50	-	26.5
Gain (Loss) on Sale of Assets	-40	-40	-40	-10	-20.5	-59.6
Pretax Income	30,450	29,160	21,630	23,690	36,835	26,660
Income Tax Expense	7,390	7,250	5,630	5,450	7,231	6,818
Net Income	23,060	21,910	16,000	18,240	29,605	19,843
Net Income to Common	23,060	21,910	16,000	18,240	29,605	19,843
Net Income Growth	37.75%	36.94%	-12.28%	-38.39%	49.19%	44.15%
Shares Outstanding (Basic)	266	265	265	265	265	265
Shares Outstanding (Diluted)	266	265	265	265	265	265
EPS (Basic)	86.82	82.53	60.27	68.71	111.52	74.75
EPS (Diluted)	86.82	82.53	60.27	68.69	111.52	74.75
EPS Growth	37.67%	36.93%	-12.26%	-38.41%	49.19%	44.16%
Free Cash Flow	-	2,150	2,580	19,860	11,986	10,367
Free Cash Flow Per Share	-	8.10	9.72	74.81	45.15	39.05
Dividend Per Share	-	30.000	30.000	30.000	30.000	20.000
Dividend Growth	-	-	-	-	50.00%	25.00%
Gross Margin	60.34%	60.20%	57.27%	57.85%	64.66%	64.46%
Operating Margin	27.57%	27.46%	23.34%	26.09%	39.87%	37.52%
Profit Margin	23.89%	23.41%	20.39%	23.48%	33.04%	28.47%
Free Cash Flow Margin	-	2.30%	3.29%	25.57%	13.38%	14.88%
EBITDA	30,650	29,680	22,050	23,640	38,801	28,666
EBITDA Margin	31.75%	31.71%	28.11%	30.44%	43.30%	41.13%
D&A For EBITDA	4,040	3,980	3,740	3,380	3,075	2,518
EBIT	26,610	25,700	18,310	20,260	35,726	26,148
EBIT Margin	27.57%	27.46%	23.34%	26.09%	39.87%	37.52%
Effective Tax Rate	24.27%	24.86%	26.03%	23.00%	19.63%	25.57%
Revenue as Reported	100,440	97,120	81,840	81,120	90,737	70,320
Advertising Expenses	-	-	-	-	1.6	0.7

Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.